Connor, Clark & Lunn Investment Management (CC&L)
BTAI icon

Connor, Clark & Lunn Investment Management (CC&L)’s BioXcel Therapeutics BTAI Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,091
Closed -$206K – 1227
2022
Q3 		$206K Buy
+1,091
New +$253K ﹤0.01% 990

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BTAI Position: Q4 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of BioXcel Therapeutics (BTAI) in Q4 2022, closing a stake of 1,091 shares — an estimated $206K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BTAI in Q3 2022 and held it in 1 quarter. The position peaked at $206K in Q3 2022. 83 funds tracked by Wall St. Rank hold BTAI as of Q4 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining BioXcel Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 1,091 BioXcel Therapeutics shares in Q4 2022, an estimated $206K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BioXcel Therapeutics in Q3 2022 and held it in 1 quarter.
  • Connor, Clark & Lunn Investment Management (CC&L)'s BioXcel Therapeutics position peaked at $206K in Q3 2022.
  • 83 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q4 2022, filed 10 Feb 2023.